BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

173 related articles for article (PubMed ID: 34723845)

  • 1. Progression of Peritoneal Mesothelioma In Situ to Invasive Mesothelioma Arising in the Setting of Endometriosis With Germline BAP1 Mutation: A Case Report.
    Fels Elliott DR; Travieso JL; As-Sanie S; Hrycaj SM; Lieberman RW; Myers JL; Huang T
    Int J Gynecol Pathol; 2022 Sep; 41(5):535-540. PubMed ID: 34723845
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Detecting germline BAP1 mutations in patients with peritoneal mesothelioma: benefits to patient and family members.
    Kittaneh M; Berkelhammer C
    J Transl Med; 2018 Jul; 16(1):194. PubMed ID: 30001711
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Mesothelioma in situ of the peritoneum: report of three cases and review of the literature.
    Symes E; Tjota M; Cody B; Kindler H; Mitchell O; Witmer H; Turaga K; Mueller J; Krausz T; Husain AN; Li H
    Histopathology; 2024 Feb; 84(3):492-506. PubMed ID: 38084880
    [TBL] [Abstract][Full Text] [Related]  

  • 4. BAP1 Is Altered by Copy Number Loss, Mutation, and/or Loss of Protein Expression in More Than 70% of Malignant Peritoneal Mesotheliomas.
    Leblay N; Leprêtre F; Le Stang N; Gautier-Stein A; Villeneuve L; Isaac S; Maillet D; Galateau-Sallé F; Villenet C; Sebda S; Goracci A; Byrnes G; McKay JD; Figeac M; Glehen O; Gilly FN; Foll M; Fernandez-Cuesta L; Brevet M
    J Thorac Oncol; 2017 Apr; 12(4):724-733. PubMed ID: 28034829
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Molecular Analysis of a Patient With Neurofibromatosis 2 (NF2) and Peritoneal Malignant Mesothelioma.
    Glass C; Sholl LM; Landgraf JR; Chirieac L; Roggli VL
    Am J Surg Pathol; 2020 Feb; 44(2):288-292. PubMed ID: 31567203
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Malignant mesothelioma in situ: morphologic features and clinical outcome.
    Churg A; Galateau-Salle F; Roden AC; Attanoos R; von der Thusen JH; Tsao MS; Chang N; De Perrot M; Dacic S
    Mod Pathol; 2020 Feb; 33(2):297-302. PubMed ID: 31375770
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Genomic profiling of malignant peritoneal mesothelioma reveals recurrent alterations in epigenetic regulatory genes BAP1, SETD2, and DDX3X.
    Joseph NM; Chen YY; Nasr A; Yeh I; Talevich E; Onodera C; Bastian BC; Rabban JT; Garg K; Zaloudek C; Solomon DA
    Mod Pathol; 2017 Feb; 30(2):246-254. PubMed ID: 27813512
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The value of BRCA-1-associated protein 1 expression and cyclin-dependent kinase inhibitor 2A deletion to distinguish peritoneal malignant mesothelioma from peritoneal location of carcinoma in effusion cytology specimens.
    Althakfi W; Gazzo S; Blanchet M; Isaac S; Piaton E; Villeneuve L; Glehen O; Gilly FN; Brevet M
    Cytopathology; 2020 Jan; 31(1):5-11. PubMed ID: 31713897
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Molecular characterization of diffuse malignant peritoneal mesothelioma.
    Hung YP; Dong F; Torre M; Crum CP; Bueno R; Chirieac LR
    Mod Pathol; 2020 Nov; 33(11):2269-2279. PubMed ID: 32504035
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Mesothelioma patients with germline BAP1 mutations have 7-fold improved long-term survival.
    Baumann F; Flores E; Napolitano A; Kanodia S; Taioli E; Pass H; Yang H; Carbone M
    Carcinogenesis; 2015 Jan; 36(1):76-81. PubMed ID: 25380601
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prevalence of BRCA-1 associated protein 1 germline mutation in sporadic malignant pleural mesothelioma cases.
    Rusch A; Ziltener G; Nackaerts K; Weder W; Stahel RA; Felley-Bosco E
    Lung Cancer; 2015 Jan; 87(1):77-9. PubMed ID: 25468148
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Genomic profiling of multiple primary cancers including synchronous lung adenocarcinoma and bilateral malignant mesotheliomas: Identification of a novel BAP1 germline variant.
    Shinozaki-Ushiku A; Kohsaka S; Kage H; Oda K; Miyagawa K; Nakajima J; Aburatani H; Mano H; Ushiku T
    Pathol Int; 2020 Oct; 70(10):775-780. PubMed ID: 32583627
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Integrated Histogenetic Analysis Reveals
    Bochtler T; Endris V; Reiling A; Leichsenring J; Schweiger MR; Klein S; Stögbauer F; Goeppert B; Schirmacher P; Krämer A; Stenzinger A
    J Natl Compr Canc Netw; 2018 Jun; 16(6):677-682. PubMed ID: 29891518
    [TBL] [Abstract][Full Text] [Related]  

  • 14. BAP1 GERMLINE MUTATION WITH IRIDOCILIOCHOROIDAL MELANOMA AND MALIGNANT PERITONEAL MESOTHELIOMA.
    Yaghy A; Lim LA; Mashayekhi A; Shields CL
    Retin Cases Brief Rep; 2022 Mar; 16(2):194-198. PubMed ID: 31895725
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A Tumor-Specific Neo-Antigen Caused by a Frameshift Mutation in BAP1 Is a Potential Personalized Biomarker in Malignant Peritoneal Mesothelioma.
    Lai J; Zhou Z; Tang XJ; Gao ZB; Zhou J; Chen SQ
    Int J Mol Sci; 2016 May; 17(5):. PubMed ID: 27187383
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Diagnostic value of BRCA1-associated protein-1, glucose transporter-1 and desmin expression in the discrimination between reactive mesothelial proliferation and malignant mesothelioma in tissues and effusions.
    Önder S; Özogul E; Koksal D; Sarinc Ulasli S; Firat P; Emri S
    Cytopathology; 2019 Nov; 30(6):592-600. PubMed ID: 31165505
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Testing for BAP1 loss and CDKN2A/p16 homozygous deletion improves the accurate diagnosis of mesothelial proliferations in effusion cytology.
    Chevrier M; Monaco SE; Jerome JA; Galateau-Salle F; Churg A; Dacic S
    Cancer Cytopathol; 2020 Dec; 128(12):939-947. PubMed ID: 32678499
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Fluorescence in situ hybridization (FISH) provides estimates of minute and interstitial BAP1, CDKN2A, and NF2 gene deletions in peritoneal mesothelioma.
    Brich S; Bozzi F; Perrone F; Tamborini E; Cabras AD; Deraco M; Stacchiotti S; Dagrada GP; Pilotti S
    Mod Pathol; 2020 Feb; 33(2):217-227. PubMed ID: 31570769
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Malignant Peritoneal Mesothelioma in an Adolescent Male With BAP1 Deletion.
    Taylor S; Carpentieri D; Williams J; Acosta J; Southard R
    J Pediatr Hematol Oncol; 2015 Jul; 37(5):e323-7. PubMed ID: 25222065
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Malignant mesothelioma in situ: diagnostic and clinical considerations.
    Pulford E; Henderson DW; Klebe S
    Pathology; 2020 Oct; 52(6):635-642. PubMed ID: 32829890
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.